Close Menu

exome sequencing

In a Twitter message dated Dec. 4, the company said it is suspending its US operations for the time being "due to an unexpected adverse financing situation."

Recent studies question the clinical utility of tumor mutational burden as a biomarker for immuno-oncology response, and the FDA clearance includes no therapeutic indications.

The company is hoping that the comprehensive solution will help bring on more pharma customers and offer extended opportunities for current users.

The approval of its Omics Core assay for tumor-normal mutational profiling opens the door for payor reimbursement, which is key to reaching profitability, NantHealth said.

In PLOS this week: Mycobacterium abscessus linked to gastric conditions, placental gene expression changes associated with preterm birth, and more.

Analyzing patient exome sequence data, investigators identified germline variants with apparent ties to estrogen receptor-positive breast cancer recurrence.

Under the non-exclusive agreement, the firms will make Twist's portfolio of NGS target enrichment products available for MGI's sequencing platforms.

In Nucleic Acids Research this week: ways to find cell death or proliferation signatures, Han Chinese population genome database, and more.

In PNAS this week: recurrent inactivation of DEPDC5 in gastrointestinal stromal tumors, taxonomic reliability of GenBank sequences, and more.

Exome sequences from dozens of cervical cancer tumor or primary cell line samples revealed recurrent alterations affecting ERBB2/HER2 and PIK3CA pathways.

Pages

Forensic genetic firm Verogen has bought the genetic genealogy site GEDmatch.

Researchers have 3D-printed plastic bunnies that encase the information needed to make more such bunnies in DNA, according to Discover magazine.

Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.

In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.